QD Clinic: Allopurinol for All Gout? Not Quite Dr. Brian Jaros, Chicago, discusses the use of allopurinol. https://t.co/XENBDqZ2Z6 https://t.co/KFTZwuYVLI

🔎Does the type of TNFi failure impact response to subsequent therapy in patients with RA? Explore post hoc findings from SELECT-SWITCH comparing a switch to a JAKi vs treatment with a second TNFi: https://t.co/Q5zndXJ2R3 Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/1PMWUDlOuC

QD Clinic: When There's Doubt in Gout Dr. Eric Dein discusses how imaging was used in correctly diagnosing a mid-foot symptom in gout. https://t.co/FNI6rlOz1O https://t.co/Xpw98DiEvs

Gout Imaging in Care Gout is all about the crystals and the consequences of the disease are due to the inflammation they cause. Getting rid of urate crystals is the ultimate goal in gout, as we now know that it leads to the risk zero of flares and it normalizes the https://t.co/DGuiTOtQFa

Saliva and Uric Acid Testing A recent report from China reaffirms the potential utility of salivary uric acid (UA) testing delivers smartphone-guided, enzyme-free gout screening at home for pennies per test. https://t.co/VtvJuPNEWA https://t.co/pdBmy5JoQd

Gout is under-diagnosed & under-treated gout in women, Asians, Blacks, CKD Stages 3–5, elderly, transplant recipients, and Rheum patients on calcineurin inhibitors. For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/XWal7tB13k

Four Things About Allopurinol Hypersensitivity Syndrome Dr. Robert Terkeltaub discusses allopurinol hypersensitivity syndrome in gout patients. https://t.co/5seiyfVLW1 https://t.co/0A1Rtk9hzS

Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf https://t.co/qvxKgvBzWu

Genicular artery embolization for knee OA does not work in a 12-mos randomized sham-controlled trial of 58 pts. Pain scores improved equally in both groups https://t.co/7wwmzpTaNL https://t.co/8MsRXqKDo2

ARTIC trial enrolled 234 DMARD naive RA (<2yrs) pts; 15.4% (36) were seronegative (SNRA). @enrollment SNRA worse than SPRA(+) w/ higher SJC (17 vs 8, p<0.001), DAS28 (3.9 vs 3.4, p=0.03), US scores (55 vs 25, p<0.001), MD global (49 vs 39, p=0.006). No diff in Sharp score, https://t.co/xDxQKY8ZG2

Intl consortium (10 EU countries) of 3952 RA pts, 184 MACE events seen 1985-2012. MACE risk signif assoc w/ DAS28 (HR 1.18;1.03-1.35), but NOT RF (HR 1.26; 0.82 to 1.94) or ACPA (HR 1.25; 0.85 to 1.83). RA activity assoc w/ MACE seen in seronegative and double positive https://t.co/RGO5IAM5oL

Glucocorticoid use in 1st yr of 574 newly DX RA cases-- 75% recv GC in 1st yr; 313 (55%) Rx at 1st visit. (m GC dose =9.3 mg/day. 1/2 (47%) recv IA GC injx. 20% had 1st yr infx. Risk of infx was NS (RR 1.13; 0.77 to 1.67) for 0-10 mg/d vs no GC https://t.co/s9YaGZsUjr https://t.co/ESHvVK1Egx